NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
UroGen Pharma Ltd. URGN
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$109.8M
▲ 21.4% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-139.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 109.8M
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 140 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-113.7%
Net margin-139.8%
Return on assets-63.1%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+56.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+19.5%
+56.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+118.1%
Change, 10 years—
The share count grew 118% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 200.5M
total assets, end of FY2025
Total assetsUSD 200.5M
EquityUSD -105.5M
CashUSD 110.7M
Gross debtUSD 122.2M
Net debtUSD 11.5M
Current ratio4.01×
Net debt stands at -11% of equity.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
·
·
Net income $B
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
·
−4.96
−5.90
−5.12
−4.80
−2.14
−1.91
−5.88
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
−211.6
−92.9
−77.8
−95.4
−47.2
−11.9
−77.9
Shares out B
0.05
0.04
0.03
0.02
0.02
0.02
0.02
0.02
0.01
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
40 of 40
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed